Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCW Biologics Inc. (NASDAQ: HCWB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company developing fusion protein immunotherapies for inflammation-driven and age-related diseases, HCW Biologics uses its SEC filings to report on clinical progress, licensing transactions, financing activities, and Nasdaq listing status.
Investors can review Form 10-K and Form 10-Q filings for detailed discussions of the company’s TOBI and TRBC platforms, pipeline candidates such as HCW9302, HCW11-040, HCW11-018b, and HCW11-006, risk factors, and management’s analysis of operations and liquidity. Form 8-K current reports highlight material events, including warrant inducement agreements that generated gross proceeds from the exercise of existing warrants, securities purchase agreements, licensing and co-development arrangements with partners like Beijing Trimmune Biotech Co., Ltd., and notices from Nasdaq regarding compliance with Listing Rule 5550(b)(1) for continued listing.
Users can also track NT 10-Q notifications of late filings, which explain delays in quarterly reports, and amended 8-K filings that correct or update prior disclosures. Where applicable, Form 4 insider transaction reports can be reviewed to see equity dealings by officers, directors, or significant shareholders, providing additional context on insider activity.
Stock Titan’s AI tools summarize lengthy filings, highlight key terms such as going concern discussions, equity financing plans, and license fee structures, and surface references to clinical milestones like the initiation and design of the Phase 1 trial for HCW9302. Real-time updates from EDGAR ensure that new HCWB filings appear promptly, while AI-generated overviews help users quickly understand how each document relates to the company’s pipeline, partnerships, capital structure, and Nasdaq listing obligations.
HCW Biologics Inc. presents an in-depth business overview as a clinical-stage immunotherapy company focused on diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated dysplasia.
The company’s lead candidate HCW9302, an IL‑2 fusion protein, entered a Phase 1 trial in alopecia areata in November 2025, with two active U.S. sites and ongoing dose escalation to establish a recommended Phase 2 dose. Preclinical programs include the “Big BiTE” T‑cell engager HCW11‑018b for solid tumors and checkpoint fusion HCW11‑040 initially targeting bronchopulmonary dysplasia.
HCW highlights commercial‑ready reagents HCW9206 and HCW9201 for CAR‑T and NK cell manufacturing, extensive patent coverage for its TOBI and TRBC platforms, and out‑licensing deals with Wugen and Trimmune. As of March 25, 2026, common shares outstanding total 6,734,104, and non‑affiliate equity value was about $6.2 million as of June 30, 2025.
HCW Biologics Inc. reported fourth quarter and full-year 2025 results showing very limited revenue and ongoing losses alongside financing and listing pressures. Revenue was $27,010 for the quarter and $54,232 for 2025, down sharply from $2.6 million in 2024, mainly due to changes in a licensing arrangement.
The company cut operating expenses to $13.2 million in 2025 from $30.4 million in 2024, helped by a $5.5 million gain tied to resolving prior legal fees. Net loss improved to $7.96 million in 2025 from $30.0 million in 2024, but cash fell to $1.95 million as of December 31, 2025.
Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months without new funding. HCW also received a new Nasdaq notice on March 26, 2026 for failing to maintain the $1 minimum bid price after a prior reverse stock split and plans to appeal. On the business side, the company initiated a Phase 1 trial of its lead autoimmune candidate HCW9302 in alopecia areata and received a $3.5 million upfront fee for licensing preclinical molecule HCW11-006, plus a minority equity stake and potential milestones and royalties.
HCW Biologics Inc. entered a material license agreement for its fusion immunotherapy candidate HCW11-006, securing an upfront license fee valued at $7.0 million. This consists of a $3.5 million cash payment and a $3.5 million in-kind payment via a transferable equity interest in its licensee, Beijing Trimmune Biotech.
Trimmune will lead development and commercialization of HCW11-006, with a Phase 1 clinical study in China expected in the first half of 2027 and will bear all trial costs. HCW Biologics remains eligible for development milestone payments, double-digit royalties on future product sales, and a share of proceeds from future transactions involving HCW11-006.
The company also negotiated a payment-, milestone-, and royalty-free option to recapture rights to HCW11-006 for in vivo use in the United States, Canada, Central America and South America after completion of the Phase 1 study in China, and granted Trimmune an option to license regional China rights to its clinical-stage molecule HCW9302.
HCW Biologics Inc. is calling a virtual special stockholder meeting on April 27, 2026 to approve two warrant-related actions tied to a recent follow-on public offering.
Proposal One seeks approval, under Nasdaq Listing Rule 5635(d), for the issuance of up to 2,477,292 shares of common stock upon exercise of Common Stock Purchase Warrants issued in the February 2026 unit offering. Without approval, warrant exercises are capped at 1,646,056 shares, or about 19.99% of pre-deal outstanding shares.
Proposal Two asks stockholders to approve repricing previously issued warrants covering up to 3,020,410 shares, reducing the exercise price from $2.41 to $0.6055 per share and approving share issuance upon exercise. The company explains that approval of both proposals could significantly dilute existing stockholders’ economic and voting interests but may improve the likelihood of warrant exercises, provide additional capital, and support continued Nasdaq listing compliance. The board recommends voting FOR both proposals.
HCW Biologics Inc. is asking stockholders to approve two Nasdaq-related actions at a virtual Special Meeting on April 27, 2026: permission to issue up to 2,477,292 shares upon exercise of Common Warrants issued in the February 2026 follow-on offering, and approval to reprice Prior Warrants to an exercise price of $0.6055 enabling issuance of up to 3,020,410 shares if exercised. The Board recommends a FOR vote on both proposals. The record date for voting is March 3, 2026, and materials will be mailed beginning on or about March 13, 2026.
HCW Biologics Inc. reports that a Nasdaq Hearings Panel determined on February 26, 2026 that the company has regained compliance with all continued listing rules of The Nasdaq Capital Market. This follows an earlier Panel decision that gave HCW Biologics until December 31, 2025 to meet the Equity Rule 5550(b)(1) and until February 16, 2026 to satisfy all other listing standards.
The company will remain under a one-year Mandatory Panel Monitor starting January 7, 2026. If it again falls out of compliance with the Equity Rule during this period, Nasdaq staff must issue a delist determination without providing any cure or additional compliance period, though the company could request a new hearing. Management highlighted that maintaining compliance supports ongoing access to public capital markets to fund its clinical-stage immunotherapy programs.
HCW Biologics Inc. entered into a follow-on public offering of 2,477,292 units at $0.6055 per unit, raising approximately $1.5 million in gross proceeds. Each unit includes one share of common stock or a pre-funded warrant plus one common stock warrant.
The common stock warrants carry a $0.6055 exercise price, become exercisable only after stockholder approval under Nasdaq rules, and expire five years after that approval. Pre-funded warrants are exercisable immediately at $0.0001 per share and remain outstanding until fully exercised.
The company also agreed, subject to stockholder approval, to reduce the exercise price of existing warrants to purchase up to 3,020,410 shares from $2.41 to $0.6055 per share. Net proceeds are intended for preclinical and clinical development, including trials for lead candidate HCW9302, and for general corporate purposes.
HCW Biologics Inc. is offering 2,477,292 Units, each consisting of one share of Common Stock (or a Pre-Funded Warrant in certain cases) and one Common Stock Warrant, at $0.6055 per Unit for gross proceeds of approximately $1.5 million on a reasonable best efforts basis.
Each Common Stock Warrant is exercisable for one share at an exercise price of $0.6055 and expires five years after any required Shareholder Approval. Pre-Funded Warrants are exercisable at $0.0001 and offered to avoid beneficial ownership exceeding 4.99% (or up to 9.99% at holder election). The offering is expected to close in a single issuance and delivery is anticipated on or about February 19, 2026. The Company disclosed a Nasdaq quoted share price of $0.6011 as of February 17, 2026.
HCW Biologics Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,957 shares, representing 9.99% of the company's common stock. The filing states shared voting and dispositive power over the 400,957 shares.
The Schedule 13G notes the Master Fund, a Cayman Islands exempted company and advisory client of Armistice Capital, has the right to receive dividends or proceeds from sale of the reported securities. The filing is a joint statement by Armistice Capital and Steven Boyd.
HCW Biologics Inc. is filing an S-1 to offer up to 7,691,124 Units, each made up of one share of common stock (or a pre-funded warrant) plus one common stock warrant, on a reasonable best efforts basis for assumed gross proceeds of about $5 million.
The offering has no minimum, no escrow and may close with significantly less capital raised, which the company plans to use mainly for clinical development of HCW9302, broader R&D, business development, IP expansion and general corporate purposes. New investors face immediate dilution, and common stock warrants will only be exercisable if required shareholder approval is obtained.
The prospectus highlights substantial doubt about HCW Biologics’ ability to continue as a going concern, significant past-due payables including construction and legal obligations, and a history of Nasdaq listing compliance issues, though the company recently regained compliance with the equity rule. It also details a restructured license with Trimmune for HCW11-006, providing a $3.5 million upfront package split between cash and equity, and describes early-stage clinical progress for autoimmune indications.